Navigation Links
Marijuana Extract May Not Relieve MS Spasms: Review
Date:12/12/2012

By Alan Mozes
HealthDay Reporter

WEDNESDAY, Dec. 12 (HealthDay News) -- A cannabis-based prescription drug called Sativex, used to treat debilitating muscle spasms in multiple sclerosis (MS) patients, is the subject of a large new evidence review. Whether the drug -- licensed for use in the United Kingdom -- actually gets the job done remains uncertain.

Cannabinoids are active ingredients in marijuana. Sativex is not currently approved by the U.S. Food and Drug Administration, which considers it an investigational drug as clinical trials are under way.

In Britain, Sativex mouth spray is prescribed for patients only as an alternative treatment when standard therapies fail to provide adequate symptom relief.

And now a British team's review of previous studies upon which its initial U.K. approval had been granted suggests that although Sativex appeared to offer some benefit, the studies themselves contain design flaws or insufficiencies that may make the conclusions unreliable.

"Our findings were that the medicine has a small beneficial effect," said David Phizackerley, the London-based deputy editor of the journal Drug and Therapeutics Bulletin, which published the study Dec. 12.

"However, we identified problems with the clinical trials of the drug," he added. "The trials compared the drug against placebo rather than against another drug, some of the trials were short, some included small numbers of patients; some trials didn't show a benefit from using the drug and some trials used a dose greater than the recommended dose," Phizackerley said.

"[So] at the moment there is limited evidence that this particular formulation of cannabis extract has a small beneficial effect in relieving the symptoms of spasticity in patients with MS," he explained.

The authors stressed that their review focused solely on investigations of the Sativex formulation. None of the studies explored the use of marijuana in its recreational or homegrown form for the treatment of spasticity, which afflicts about 60 percent of MS patients.

That said, the review team noted that many studies were of limited clinical usefulness, given that patients only took Sativex for between six weeks and four months. No study set out to compare Sativex against other standard spasm-control medications, whereas others had patients routinely take Sativex beyond the maximum use (12 sprays daily) approved by U.K. authorities.

However, the British research team did cite one study that was well designed. And the result of that investigation: Sativex patients fared no better than patients not given the drug.

Sativex is by no means a cheap therapy, Phizackerley noted. At roughly $2.25 per spray, it costs upwards of 10 times more than standard spasm-control drugs.

So while acknowledging that additional research is now exploring a range of cannabis extract formulations, including tablets and capsules, he and his colleagues concluded that for the moment there is not yet enough evidence to warrant recommending that doctors and MS patients turn to this medication as a proven approach for the relief of spasms.

Nicholas LaRocca, vice president of health care delivery and policy research with the National Multiple Sclerosis Society, said that although the Sativex option is not an approved drug intervention in the United States, "there is obviously a need for additional therapies for the many symptoms of MS."

LaRocca said: "I think this analysis speaks for itself. Clearly, right now there's insufficient data available to recommend Sativex for targeting spasticity. And because it's not available here, we mostly just have anecdotal reporting from patients who go ahead and use marijuana on their own. And there's an inability to verify these reports, which just raises questions about uncontrolled long-term use and safety."

So, LaRocca added, "for now it remains an open question. And certainly there needs to be more research to look into this issue more deeply, because the larger issue is that there are treatments available, but they don't necessarily work as well for everyone, because everyone with MS is a little bit different."

More information

For more on multiple sclerosis, visit the U.S. National Institute of Neurological Disorders and Stroke.

SOURCES: David Phizackerley, deputy editor, Drug and Therapeutics Bulletin, BMJ Group, London; Nicholas G. LaRocca, Ph.D., vice president, health care delivery and policy research, National Multiple Sclerosis Society, New York City; Dec. 12, 2012, Drug and Therapeutics Bulletin


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study shows no evidence medical marijuana increases teen drug use
2. 1 in 10 Fibromyalgia Patients Uses Marijuana to Ease Pain
3. Diverted Medical Marijuana Use Common Among Teens: Study
4. Adolescents in substance abuse programs report using others med marijuana
5. Heavy Marijuana Use in Teen Years May Lower IQ Later
6. Marijuana use may increase risk of testicular cancer
7. Algae extract increases good cholesterol levels, Wayne State research finds
8. New options for ease and accuracy in extraction of rare cells or separating blood
9. Deer Antler Velvet Extract to Advertise with MMA World Wide
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Adds Prescription Strength Saffron Extract Diet Pills to Their Exhaustive Product Line
11. New Pill Might Relieve Severe Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Marijuana Extract May Not Relieve MS Spasms: Review 
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology: